Mateon Therapeutics Inc (OXGN), Company and Other News, second quarter 2018 earnings report

Redemption of Losses but Revenues Unchanged

NEWS BETA

Mateon Therapeutics Inc announced second quarter 2018 operating shortfall of $-0.898 millions

For the second quarter 2018 Mateon Therapeutics Inc decreased loss of $-0.02 per share compare to $-0.15 a year ago and improved from $-0.03 per share from the previous quarter.

Sales remained unchanged to $0 millions from $0 millions in the same quarter a year ago and sequentially from $0 millions.

In the second quarter 2018 Mateon Therapeutics Inc reported net loss of $-1 million, instead of deficit of $-4 millions in the same quarter a year ago.

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. Free Stock Market News Feeds

Copyright © 2018 CSIMarket, Inc. All rights reserved. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)
Intraday Data provided by Barchart and subject to terms of use. To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Stock Price, historical and current end-of-day data provided by eoddata. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Barchart and Eoddata. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071

Redemption of Losses but Revenues Unchanged

Mateon Therapeutics Inc announced second quarter 2018 operating shortfall of $-0.898 millions

Stocks

Economy

Industries

Other OXGN's Earnings Reports